School Access to Emergency Epinephrine Act

H.R. 3627/S. 1884, School Access to Emergency Epinephrine Act; S. 3187, Food and Drug Administration Safety and Innovation Act (FDASIA), Title 3, Generic Drug User Fee Amendment (GDUFA), Title 4, Fees Relating to Biosimilar Biological Products; Pharmaceutical Distribution Supply Chain; HIV/AIDS; Patent Settlements; Biosimilars; Electronic Distribution of Labeling of Prescription Drugs

Client expense: $410,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3627 and S. 1884 School Access to Emergency Epinephrine Act all provisions.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FDA Conflict of Interest issue and FDA issues affecting Allergists and their patients. Monitor and track: Health Information Technology issues; Asthma & Allergy Legislation, Clinical Research, healthcare quality, patient safety initiatives and health care reform. Support H.R. 451, Healthcare Truth & Transparency Act of 2011. HR 1852, S. 958 support authorization of Children Hospital Graduate Medical Education program. H.R. 6284, Breath of Fresh Air, H.R. 3627 & S. 1884, School Access to Emergency Epinephrine, H.R. 6190, Asthma Inhaler Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Lobbying with regard to medical malpractice reform proposals generally. H.R.5 (Help Efficient, Accessible, Low-cost, Timely Healthcare Act of 2011); to set conditions for lawsuits arising from health care liability claims regarding health care goods or services or any medical product affecting interstate commerce. H.R. 6684 (Spending Reduction Act of 2012); specific interest in proivions relating to medical malpractice reform. S.1884/H.R.3627 (School Access to Emergency Epinephrine Act); specific interest in civil liability limitations for school employees and agents and prescribing physicians in relation to the administration of epinephrine.

Client expense: $790,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office

Issues related to the School Access to Emergency Epinephrine Act (HR 3627; S 1884).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board; "HR 4223 "Strenghthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "Safe Doses Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR 2405 and S 1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR 3627 and S 1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefence funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

REGULATION OF WIRELESS INDUSTRY S. 28, S. 415, S. 455, S. 522, S. 732, S. 799, S. 911, S. 913, S. 1151, S. 1207, S. 1212, S. 1223, S. 1308, S. 1408, S. 1549, S. 1780, S. 1784, S. 1830, S. 2008, S. 2105, S. 2151, S. 3186, S. 3291, S. 3324, S. 3342, S. 3414, S. 3703, S.J. Res. 6, H.R. 607, H.R. 611, H.R. 847, H.R. 911, H.R. 1528, H.R. 1707, H.R. 1841, H.R. 1895, H.R. 1981, H.R. 2168, H.R. 2281, H.R. 2289, H.R. 2482, H.R. 2577, H.R. 2629, H.R. 2976, H.R. 3010, H.R. 3261, H.R. 3309, H.R. 3310, H.R. 3509, H.R. 3523, H.R. 3627, H.R. 3630, H.R. 3674, H.R. 4078, H.R. 4257, H.R. 4817, H.R. 6377, H.J. Res. 37

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pharmaceutical issues, including Food and Drug Administration Safety and Innovation Act (PL 112-144), changes to the Patient Protection and Affordable Care Act (PL 111-148) Health Care & Education Reconciliation Act of 2010 (PL 111-152), including the Independent Payment Advisory Board; importation of prescription drugs; and S. 1884/H.R. 3627, School Access to Emergency Epinephrine Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General issues related to prescription drug safety and the importation of prescription drugs. Opposed amendment to PDUFA, S. 3187, that would allow unsafe importation of drugs. General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act - including issues related to the Independent Payment Advisory Board. Issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine. H.R. 2405 and S.1855, Pandemic and All Hazards Preparation Act Reauthorization of 2011 - all provisions. H.R. 3627 and S.1884, School Access to Emergency Epinephrine Act - all provisions. Education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues. Education and awareness of Dengue. All provisions of H. Res. 295, Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act including issues related to the Independent Payment Advisory Board; "HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of pandemic and biodefense funding in FY2012 and related international intellectual property issues; and education and awareness of dengue.

Client expense: $1,590,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Vaccine related issues and general biological issues generally, as well as the Independent Payment Advisory Board (IPAB), dengue fever, and H.R. 3627/S. 1884, School Access to Emergency Epinephrine Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 3627 and S. 1884 School Access to Emergency Epinephrine Act all provisions.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

FDA Conflict of Interest issue and FDA issues affecting Allergists and their patients. Monitor and track: Health Information Technology issues; Asthma & Allergy Legislation, Clinical Research, healthcare quality, patient safety initiatives and health care reform. Support H.R. 451, Healthcare Truth & Transparency Act of 2011. HR 1852, S. 958 support authorization of Children Hospital Graduate Medical Education program. H.R. 6284, Breath of Fresh Air, H.R. 3627 & S. 1884, School Access to Emergency Epinephrine, H.R. 6190, Asthma Inhaler Act.

Client expense: Not reported · Firm income: $30,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

REGULATION OF WIRELESS INDUSTRY S. 28, S. 415, S. 455, S. 522, S. 732, S. 799, S. 911, S. 913, S. 1151, S. 1207, S. 1212, S. 1223, S. 1308, S. 1408, S. 1549, S. 1780, S. 1784, S. 1830, S. 2008, S. 2105, S. 2151, S. 3186, S. 3291, S. 3324, S. 3342, S. 3414, S.J. Res. 6, H.R. 607, H.R. 611, H.R. 847, H.R. 911, H.R. 1528, H.R. 1707, H.R. 1841, H.R. 1895, H.R. 1981, H.R. 2168, H.R. 2281, H.R. 2289, H.R. 2482, H.R. 2577, H.R. 2629, H.R. 2976, H.R. 3010, H.R. 3261, H.R. 3309, H.R. 3310, H.R. 3509, H.R. 3523, H.R. 3627, H.R. 3630, H.R. 3674, H.R. 4078, H.R. 4257, H.R. 4817, H.R. 6377, H.J. Res. 37

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Lobbying with regard to medical malpractice reform proposals generally. H.R.5 (Help Efficient, Accessible, Low-cost, Timely Healthcare Act of 2011); to set conditions for lawsuits arising from health care liability claims regarding health care goods or services or any medical product affecting interstate commerce. S.2264/H.R.4345 (Domestic Fuels Protection Act); to provide liability protection for claims based on the design, manufacture, sale, offer for sale, introduction into commerce, or use of certain fuels and fuel additives. S.1884/H.R.3627 (School Access to Emergency Epinephrine Act); specific interest in civil liability limitations for school employees and agents and prescribing physicians in relation to the administration of epinephrine.

Client expense: $1,150,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Housing & Urban Development, Dept of (HUD), SENATE, White House Office

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IBAP); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; H.R. 2529 "Restoring Access to Medication Act" - all provisions; H.R. 3627 and S. 1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenze pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; H.R. 2405 and S. 1855 education and awareness of Dengue; H.R. 4223 "Strengthening and Focusing Enforcement to deter Organized Stealing and Enhance Safety Act of 2012" or "Safe Doses Act"; H. Res. 295 "Promoting increased awareness, diagnosis and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with the disease; H.R. 436 "Healthcare Cost Reduction Act of 2012"; awareness and issues related to diabetes and patient access to diabetes care.

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the School Access to Emergency Epinephrine Act (HR 3627; S 1884).

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

General issues related to prescription drug safety and the importation of prescription drugs. Opposed amendment to PDUFA, S. 3187, that would allow unsafe importation of drugs. General issues regarding implementation of Public Law 111-148, Patient Protection and Affordable Care Act - including issues related to the Independent Payment Advisory Board and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in H.R.2529, Restoring Access to Medication Act and H.R.436 - Health Care Cost Reduction Act of 2012. Awareness and issues related to diabetes and patient access to diabetes care. H.R.4223, Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012 or "SAFE DOSES Act" - all provisions. Issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine. H.R. 2405 and S.1855, Pandemic and All Hazards Preparation Act Reauthorization of 2011 - all provisions. H.R. 3627 and S.1884, School Access to Emergency Epinephrine Act - all provisions. Education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues. Education and awareness of Dengue. All provisions of H. Res. 295, Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including issues related to the Independent Payment Advisory Board, and efforts to repeal provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; HR4223 "Strengthening and Focusing Enforcement to Deter Organized Stealing and Enhance Safety Act of 2012" or "SAFE DOSES Act" - all provisions; issues related to the continued over-the-counter availability of allergy, cough and cold medicines that contain pseudoephedrine; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue; and all provisions of H. Res. 295 "Promoting increased awareness, diagnosis, and treatment of atrial fibrillation to address the high morbidity and mortality rates and to prevent avoidable hospitalizations associated with this disease."

Client expense: $710,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

REGULATION OF WIRELESS INDUSTRY S. 28, S. 415, S. 455, S. 522, S. 732, S. 799, S. 911, S. 913, S. 1151, S. 1207, S. 1212, S. 1223, S. 1308, S. 1408, S. 1549, S. 1780, S. 1784, S. 1830, S. 2008, S. 2105, S. 2151, S. 3186, S. 3291, S. 3324, S.J. Res. 6, H.R. 607, H.R. 611, H.R. 847, H.R. 911, H.R. 1528, H.R. 1707, H.R. 1841, H.R. 1895, H.R. 1981, H.R. 2168, H.R. 2281, H.R. 2289, H.R. 2482, H.R. 2577, H.R. 2629, H.R. 2976, H.R. 3010, H.R. 3261, H.R. 3309, H.R. 3310, H.R. 3509, H.R. 3523, H.R. 3627, H.R. 3630, H.R. 3674, H.R. 4257, H.R. 4817, H.J. Res. 37

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Vaccine related issues and general biological issues generally, as well as the Prescription Drug User Fee Act (PDUFA), Independent Payment Advisory Board (IPAB), dengue fever, and H.R. 3627/S. 1884, School Access to Emergency Epinephrine Act.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Pandemic influenza, vaccine-related issues; H.R. 5901 and S. 3274, Global Investment in American Jobs Act; H.R. 3627 and S. 1884, School Access to Emergency Epinephrine Act.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223 "SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues; education and awareness of dengue.

Client expense: $1,420,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Lobbying with regard to medical malpractice reform proposals generally. H.R.5 (Help Efficient, Accessible, Low-cost, Timely Healthcare Act of 2011); to set conditions for lawsuits arising from health care liability claims regarding health care goods or services or any medical product affecting interstate commerce. H.R.5652 (Sequester Replacement Reconciliation Act); specific interest in provisions setting conditions for lawsuits arising from health care liabiltiy claims regarding health care goods or services or any medical product affecting interstate commerce. H.R.3511 (Cardiac Arrest Survival Act); to clarify liability protections regarding emergency use of automated external defibrillators. S.2264/H.R.4345 (Domestic Fuels Protection Act); to provide liability protection for claims based on the design, manufacture, sale, offer for sale, introduction into commerce, or use of certain fuels and fuel additives. S.1884/H.R.3627 (School Access to Emergency Epinephrine Act); specific interest in civil liability limitations for school employees and agents and prescribing physicians in relation to the administration of epinephrine.

Client expense: $810,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Support H.R. 3627 and S. 1884, School Access to Emergency Epinephrine Act. General issues related to prescription drug safety and the importation of prescription drugs. Opposed amendment to PDUFA, S. 3187, that would allow unsafe importation of drugs.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

issues relating to the School Access to Emergency Epinephrine Act (H.R. 3627, S. 1884)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE, U.S. Trade Representative (USTR)

General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act"; awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR 3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenze pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of Dengue; all provisions of S1002 "Safe Doses Act."

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2245/S. 296, the Preserving Access to Life-Saving Medications Act School Access to Emergency Epinephrine Act (H.R. 3627)

Client expense: Not reported · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

issues relating to the School Access to Emergency Epimephrine Act (H.R. 3627, S. 1884)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IBAP); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR 3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenze pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of Dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Repeal and defunding efforts and general issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" including the Independent Payment Advisory Board (IPAB); awareness & issues related to diabetes and patient access to diabetes care; general issues related to prescription drug safety; HR2529 "Restoring Access to Medication Act" - all provisions; HR2245 "Preserving Access to Life-Saving Medications Act of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; issues related to efforts to move pseudoephedrine products to prescription drug status; education and awareness of influenza pandemic and biodefense funding in FY2012 funding bills; education and awareness and general issues related to the reauthorization of the Pandemic and All Hazards Preparation Act; education and awareness of dengue; all provisions of S1002 "Safe Doses Act"; awareness & issues related to patient access to care for Dengue; and all provisions of draft legislation "Immunization Improvements Act of 2011."

Client expense: $750,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2245/S. 296, the Preserving Access to Life-Saving Medications Act School Access to Emergency Epinephrine Act (H.R. 3627)

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE